<p>Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 獲取免費報告) 的股價在週四的交易中達到了新的 52 周高點。該公司的股價最高達到 16.60 美元，最後交易價格為 16.2420 美元，成交量為 210470 股。該股票此前收盤價為 15.36 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾位股票研究分析師最近對該股票發表了看法。巴克萊在 12 月 8 日的研究報告中開始覆蓋 Phathom Pharmaceuticals 的股票。他們給予該公司的 “持平” 評級，並設定了 16.00 美元的目標價。雷蒙德·詹姆斯金融在 12 月 11 日的研究報告中開始覆蓋 Phathom Pharmaceuticals 的股票。他們給予該股票 “強力買入” 評級，並設定了 28.00 美元的目標價。華爾街 Zen 在 10 月 18 日的研究報告中將 Phathom Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。HC Wainwright 在 10 月 31 日的研究報告中將 Phathom Pharmaceuticals 的目標價從 20.00 美元上調至 26.00 美元，並給予該公司 “買入” 評級。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Phathom Pharmaceuticals 的 “賣出（d-）” 評級。有兩位分析師給予該股票 “強力買入” 評級，四位給予 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，Phathom Pharmaceuticals 目前的平均評級為 “適度買入”，共識目標價為 21.00 美元。</p>
<p><strong>閲讀我們關於 Phathom Pharmaceuticals 的最新研究報告</strong></p>
<h2>Phathom Pharmaceuticals 上漲 3.6%</h2>
<p>該公司的 50 日移動平均線為 14.09 美元，200 日移動平均線為 11.48 美元。該公司的市值為 11.3 億美元，市盈率為-4.16，貝塔值為 0.43。</p>
<p>Phathom Pharmaceuticals (NASDAQ:PHAT - 獲取免費報告) 最近在 10 月 30 日公佈了季度財報。該公司報告季度每股收益為（0.15 美元），超出分析師共識預期的（0.30 美元）0.15 美元。該公司在本季度的收入為 4950 萬美元，而分析師預期為 4703 萬美元。作為一個整體，研究分析師預測 Phathom Pharmaceuticals, Inc.在本年度將發佈-4.78 美元的每股收益。</p>
<h2>機構資金流入和流出</h2>
<p>一些大型投資者最近對該公司的持倉進行了調整。Jones Financial Companies Lllp 在第三季度將其在 Phathom Pharmaceuticals 的持股增加了 442.6%。Jones Financial Companies Lllp 目前擁有 2523 股該公司的股票，價值 30000 美元，此前在上個季度增持了 2058 股。雷蒙德·詹姆斯金融在第二季度購買了 Phathom Pharmaceuticals 的新股份，價值約 30000 美元。Ameritas Investment Partners Inc.在第二季度將其在 Phathom Pharmaceuticals 的持股增加了 39.3%。Ameritas Investment Partners Inc.目前擁有 4311 股該公司的股票，價值 41000 美元，此前在上個季度增持了 1216 股。法國巴黎銀行金融市場在第二季度將其在 Phathom Pharmaceuticals 的持股增加了 71.9%。法國巴黎銀行金融市場目前擁有 5072 股該公司的股票，價值 49000 美元，此前在上個季度增持了 2122 股。最後，Tower Research Capital LLC TRC 在第二季度將其在 Phathom Pharmaceuticals 的持股增加了 58.3%。Tower Research Capital LLC TRC 目前擁有 5710 股該公司的股票，價值 55000 美元，此前在上個季度增持了 2102 股。99.01% 的股票由機構投資者持有。</p>
<h2>Phathom Pharmaceuticals 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Phathom Pharmaceuticals, Inc.是一家生物製藥公司，專注於開發和商業化治療胃腸疾病的藥物。該公司在美國、歐洲和加拿大擁有一種研究性鉀競爭性酸阻滯劑（P-CAB）的權利，該藥物可以阻止胃酸分泌。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過 Phathom Pharmaceuticals</li>
<li>最大的股票虧損者 - 今日最大百分比下跌者</li>
<li>3 只便宜的分紅股票，可以戰勝通貨膨脹並支付你等待的費用</li>
<li>投資石油股票的方式和原因</li>
<li>3 只新年決議股票，可能在 2026 年反彈</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>大麻股票即將反轉：幻想還是機會？</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Phathom Pharmaceuticals 嗎？</h2>
<p>在你考慮 Phathom Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Phathom Pharmaceuticals 並不在名單上。</p>
<p>雖然 Phathom Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

PHAT

<p>Phathom Pharmaceuticals（納斯達克代碼：PHAT）達到了新的 52 周高點 16.60 美元，收盤價為 16.2420 美元。分析師的評級不一，有些給予 “強烈買入” 和 “買入” 評級，而另一些則建議 “持有” 或 “賣出”。該公司報告了超出預期的上一季度收益。機構投資者對該股票表現出更高的興趣。Phathom 專注於胃腸疾病的治療，市值為 11.3 億美元</p>

<p>Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report)'s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $16.60 and last traded at $16.2420, with a volume of 210470 shares trading hands. The stock had previously closed at $15.36.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - 獲取免費報告) 的股價在週四的交易中達到了新的 52 周高點。該公司的股價最高達到 16.60 美元，最後交易價格為 16.2420 美元，成交量為 210470 股。該股票此前收盤價為 15.36 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several equities research analysts have recently weighed in on the stock. Barclays assumed coverage on shares of Phathom Pharmaceuticals in a research report on Monday, December 8th. They set an &#34;equal weight&#34; rating and a $16.00 price objective for the company. Raymond James Financial assumed coverage on shares of Phathom Pharmaceuticals in a research report on Thursday, December 11th. They set a &#34;strong-buy&#34; rating and a $28.00 price target on the stock. Wall Street Zen raised Phathom Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, October 18th. HC Wainwright boosted their price objective on Phathom Pharmaceuticals from $20.00 to $26.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 31st. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Phathom Pharmaceuticals in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Phathom Pharmaceuticals presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $21.00.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對該股票發表了看法。巴克萊在 12 月 8 日的研究報告中開始覆蓋 Phathom Pharmaceuticals 的股票。他們給予該公司的 “持平” 評級，並設定了 16.00 美元的目標價。雷蒙德·詹姆斯金融在 12 月 11 日的研究報告中開始覆蓋 Phathom Pharmaceuticals 的股票。他們給予該股票 “強力買入” 評級，並設定了 28.00 美元的目標價。華爾街 Zen 在 10 月 18 日的研究報告中將 Phathom Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。HC Wainwright 在 10 月 31 日的研究報告中將 Phathom Pharmaceuticals 的目標價從 20.00 美元上調至 26.00 美元，並給予該公司 “買入” 評級。最後，Weiss Ratings 在 10 月 8 日的研究報告中重申了對 Phathom Pharmaceuticals 的 “賣出（d-）” 評級。有兩位分析師給予該股票 “強力買入” 評級，四位給予 “買入” 評級，兩位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，Phathom Pharmaceuticals 目前的平均評級為 “適度買入”，共識目標價為 21.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on Phathom Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Phathom Pharmaceuticals 的最新研究報告</strong></p>
</div><h2>Phathom Pharmaceuticals Trading Up 3.6%</h2>
<div class="lb-trans"><h2>Phathom Pharmaceuticals 上漲 3.6%</h2>
</div><p>The business has a 50-day moving average of $14.09 and a 200 day moving average of $11.48. The firm has a market capitalization of $1.13 billion, a P/E ratio of -4.16 and a beta of 0.43.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 14.09 美元，200 日移動平均線為 11.48 美元。該公司的市值為 11.3 億美元，市盈率為-4.16，貝塔值為 0.43。</p>
</div><p>Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) last announced its quarterly earnings data on Thursday, October 30th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.15. The firm had revenue of $49.50 million during the quarter, compared to analyst estimates of $47.03 million. As a group, research analysts forecast that Phathom Pharmaceuticals, Inc. will post -4.78 EPS for the current year.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals (NASDAQ:PHAT - 獲取免費報告) 最近在 10 月 30 日公佈了季度財報。該公司報告季度每股收益為（0.15 美元），超出分析師共識預期的（0.30 美元）0.15 美元。該公司在本季度的收入為 4950 萬美元，而分析師預期為 4703 萬美元。作為一個整體，研究分析師預測 Phathom Pharmaceuticals, Inc.在本年度將發佈-4.78 美元的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>A number of large investors have recently made changes to their positions in the business. Jones Financial Companies Lllp raised its holdings in shares of Phathom Pharmaceuticals by 442.6% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company's stock worth $30,000 after acquiring an additional 2,058 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Phathom Pharmaceuticals during the 2nd quarter worth approximately $30,000. Ameritas Investment Partners Inc. increased its holdings in Phathom Pharmaceuticals by 39.3% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,311 shares of the company's stock worth $41,000 after purchasing an additional 1,216 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Phathom Pharmaceuticals by 71.9% in the second quarter. BNP Paribas Financial Markets now owns 5,072 shares of the company's stock worth $49,000 after purchasing an additional 2,122 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Phathom Pharmaceuticals by 58.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,710 shares of the company's stock valued at $55,000 after purchasing an additional 2,102 shares in the last quarter. 99.01% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些大型投資者最近對該公司的持倉進行了調整。Jones Financial Companies Lllp 在第三季度將其在 Phathom Pharmaceuticals 的持股增加了 442.6%。Jones Financial Companies Lllp 目前擁有 2523 股該公司的股票，價值 30000 美元，此前在上個季度增持了 2058 股。雷蒙德·詹姆斯金融在第二季度購買了 Phathom Pharmaceuticals 的新股份，價值約 30000 美元。Ameritas Investment Partners Inc.在第二季度將其在 Phathom Pharmaceuticals 的持股增加了 39.3%。Ameritas Investment Partners Inc.目前擁有 4311 股該公司的股票，價值 41000 美元，此前在上個季度增持了 1216 股。法國巴黎銀行金融市場在第二季度將其在 Phathom Pharmaceuticals 的持股增加了 71.9%。法國巴黎銀行金融市場目前擁有 5072 股該公司的股票，價值 49000 美元，此前在上個季度增持了 2122 股。最後，Tower Research Capital LLC TRC 在第二季度將其在 Phathom Pharmaceuticals 的持股增加了 58.3%。Tower Research Capital LLC TRC 目前擁有 5710 股該公司的股票，價值 55000 美元，此前在上個季度增持了 2102 股。99.01% 的股票由機構投資者持有。</p>
</div><h2>Phathom Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Phathom Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.</p>
<div class="lb-trans"><p>Phathom Pharmaceuticals, Inc.是一家生物製藥公司，專注於開發和商業化治療胃腸疾病的藥物。該公司在美國、歐洲和加拿大擁有一種研究性鉀競爭性酸阻滯劑（P-CAB）的權利，該藥物可以阻止胃酸分泌。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Phathom Pharmaceuticals</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>3 Cheap Dividend Stocks That Can Beat Inflation and Pay You to Wait</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>3 New Year’s Resolution Stocks That Could Turn Around in 2026</li>
<li>What Are the FAANG Stocks and Are They Good Investments?</li>
<li>Cannabis Stocks Up for Reversal: Pipedreams or Opportunity?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過 Phathom Pharmaceuticals</li>
<li>最大的股票虧損者 - 今日最大百分比下跌者</li>
<li>3 只便宜的分紅股票，可以戰勝通貨膨脹並支付你等待的費用</li>
<li>投資石油股票的方式和原因</li>
<li>3 只新年決議股票，可能在 2026 年反彈</li>
<li>FAANG 股票是什麼，它們是好的投資嗎？</li>
<li>大麻股票即將反轉：幻想還是機會？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Phathom Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Phathom Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Phathom Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Phathom Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Phathom Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Phathom Pharmaceuticals 並不在名單上。</p>
</div><p>While Phathom Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Phathom Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Phathom Pharmaceuticals（NASDAQ:PHAT）創下一年新高 - 接下來會如何發展？